Patient characteristics associated with improved outcomes with use of an inhaled corticosteroid in preschool children at risk for asthma

Leonard B. Bacharier, Theresa W. Guilbert, Robert S. Zeiger, Robert C. Strunk, Wayne J Morgan, Robert F. Lemanske, Mark Moss, Stanley J. Szefler, Marzena Krawiec, Susan Boehmer, David Mauger, Lynn M. Taussig, Fernando Martinez

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Background: Maintenance inhaled corticosteroid (ICS) therapy in preschool children with recurrent wheezing at high-risk for development of asthma produces multiple clinical benefits. However, determination of baseline features associated with ICS responsiveness may identify children most likely to benefit from ICS treatment. Objective: To determine if demographic and atopic features predict response to ICS in preschool children at high risk for asthma. Methods: Two years of treatment with an ICS, fluticasone propionate (88 μg twice daily), was compared with matching placebo in a double-masked, randomized, multicenter study of 285 children 2 and 3 years old at high risk for asthma development. Baseline demographic and atopic features were related to clinical outcomes in a post hoc subgroup analysis. Results: Multivariate analysis demonstrated significantly greater improvement with fluticasone than placebo in terms of episode-free days among boys, white subjects, participants with an emergency department (ED) visit or hospitalization within the past year, and those who experienced more symptomatic days at baseline. Children with aeroallergen sensitization experienced greater benefits in terms of oral corticosteroid use, urgent care and ED visits, and use of supplemental controller medications. Conclusions: More favorable responses to ICS than placebo in high-risk preschool children over a 2-year period were more likely in those with a ED visit or hospitalization for asthma within the past year, children with aeroallergen sensitization, boys, and white subjects.

Original languageEnglish (US)
JournalJournal of Allergy and Clinical Immunology
Volume123
Issue number5
DOIs
StatePublished - May 2009

Fingerprint

Preschool Children
Adrenal Cortex Hormones
Asthma
Hospital Emergency Service
Placebos
Hospitalization
Demography
Respiratory Sounds
Ambulatory Care
Multicenter Studies
Therapeutics
Multivariate Analysis
Maintenance

Keywords

  • Childhood asthma
  • inhaled corticosteroids
  • response

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Patient characteristics associated with improved outcomes with use of an inhaled corticosteroid in preschool children at risk for asthma. / Bacharier, Leonard B.; Guilbert, Theresa W.; Zeiger, Robert S.; Strunk, Robert C.; Morgan, Wayne J; Lemanske, Robert F.; Moss, Mark; Szefler, Stanley J.; Krawiec, Marzena; Boehmer, Susan; Mauger, David; Taussig, Lynn M.; Martinez, Fernando.

In: Journal of Allergy and Clinical Immunology, Vol. 123, No. 5, 05.2009.

Research output: Contribution to journalArticle

Bacharier, LB, Guilbert, TW, Zeiger, RS, Strunk, RC, Morgan, WJ, Lemanske, RF, Moss, M, Szefler, SJ, Krawiec, M, Boehmer, S, Mauger, D, Taussig, LM & Martinez, F 2009, 'Patient characteristics associated with improved outcomes with use of an inhaled corticosteroid in preschool children at risk for asthma', Journal of Allergy and Clinical Immunology, vol. 123, no. 5. https://doi.org/10.1016/j.jaci.2008.12.1120
Bacharier, Leonard B. ; Guilbert, Theresa W. ; Zeiger, Robert S. ; Strunk, Robert C. ; Morgan, Wayne J ; Lemanske, Robert F. ; Moss, Mark ; Szefler, Stanley J. ; Krawiec, Marzena ; Boehmer, Susan ; Mauger, David ; Taussig, Lynn M. ; Martinez, Fernando. / Patient characteristics associated with improved outcomes with use of an inhaled corticosteroid in preschool children at risk for asthma. In: Journal of Allergy and Clinical Immunology. 2009 ; Vol. 123, No. 5.
@article{26348c26bbb548abb24227b0a361993b,
title = "Patient characteristics associated with improved outcomes with use of an inhaled corticosteroid in preschool children at risk for asthma",
abstract = "Background: Maintenance inhaled corticosteroid (ICS) therapy in preschool children with recurrent wheezing at high-risk for development of asthma produces multiple clinical benefits. However, determination of baseline features associated with ICS responsiveness may identify children most likely to benefit from ICS treatment. Objective: To determine if demographic and atopic features predict response to ICS in preschool children at high risk for asthma. Methods: Two years of treatment with an ICS, fluticasone propionate (88 μg twice daily), was compared with matching placebo in a double-masked, randomized, multicenter study of 285 children 2 and 3 years old at high risk for asthma development. Baseline demographic and atopic features were related to clinical outcomes in a post hoc subgroup analysis. Results: Multivariate analysis demonstrated significantly greater improvement with fluticasone than placebo in terms of episode-free days among boys, white subjects, participants with an emergency department (ED) visit or hospitalization within the past year, and those who experienced more symptomatic days at baseline. Children with aeroallergen sensitization experienced greater benefits in terms of oral corticosteroid use, urgent care and ED visits, and use of supplemental controller medications. Conclusions: More favorable responses to ICS than placebo in high-risk preschool children over a 2-year period were more likely in those with a ED visit or hospitalization for asthma within the past year, children with aeroallergen sensitization, boys, and white subjects.",
keywords = "Childhood asthma, inhaled corticosteroids, response",
author = "Bacharier, {Leonard B.} and Guilbert, {Theresa W.} and Zeiger, {Robert S.} and Strunk, {Robert C.} and Morgan, {Wayne J} and Lemanske, {Robert F.} and Mark Moss and Szefler, {Stanley J.} and Marzena Krawiec and Susan Boehmer and David Mauger and Taussig, {Lynn M.} and Fernando Martinez",
year = "2009",
month = "5",
doi = "10.1016/j.jaci.2008.12.1120",
language = "English (US)",
volume = "123",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Patient characteristics associated with improved outcomes with use of an inhaled corticosteroid in preschool children at risk for asthma

AU - Bacharier, Leonard B.

AU - Guilbert, Theresa W.

AU - Zeiger, Robert S.

AU - Strunk, Robert C.

AU - Morgan, Wayne J

AU - Lemanske, Robert F.

AU - Moss, Mark

AU - Szefler, Stanley J.

AU - Krawiec, Marzena

AU - Boehmer, Susan

AU - Mauger, David

AU - Taussig, Lynn M.

AU - Martinez, Fernando

PY - 2009/5

Y1 - 2009/5

N2 - Background: Maintenance inhaled corticosteroid (ICS) therapy in preschool children with recurrent wheezing at high-risk for development of asthma produces multiple clinical benefits. However, determination of baseline features associated with ICS responsiveness may identify children most likely to benefit from ICS treatment. Objective: To determine if demographic and atopic features predict response to ICS in preschool children at high risk for asthma. Methods: Two years of treatment with an ICS, fluticasone propionate (88 μg twice daily), was compared with matching placebo in a double-masked, randomized, multicenter study of 285 children 2 and 3 years old at high risk for asthma development. Baseline demographic and atopic features were related to clinical outcomes in a post hoc subgroup analysis. Results: Multivariate analysis demonstrated significantly greater improvement with fluticasone than placebo in terms of episode-free days among boys, white subjects, participants with an emergency department (ED) visit or hospitalization within the past year, and those who experienced more symptomatic days at baseline. Children with aeroallergen sensitization experienced greater benefits in terms of oral corticosteroid use, urgent care and ED visits, and use of supplemental controller medications. Conclusions: More favorable responses to ICS than placebo in high-risk preschool children over a 2-year period were more likely in those with a ED visit or hospitalization for asthma within the past year, children with aeroallergen sensitization, boys, and white subjects.

AB - Background: Maintenance inhaled corticosteroid (ICS) therapy in preschool children with recurrent wheezing at high-risk for development of asthma produces multiple clinical benefits. However, determination of baseline features associated with ICS responsiveness may identify children most likely to benefit from ICS treatment. Objective: To determine if demographic and atopic features predict response to ICS in preschool children at high risk for asthma. Methods: Two years of treatment with an ICS, fluticasone propionate (88 μg twice daily), was compared with matching placebo in a double-masked, randomized, multicenter study of 285 children 2 and 3 years old at high risk for asthma development. Baseline demographic and atopic features were related to clinical outcomes in a post hoc subgroup analysis. Results: Multivariate analysis demonstrated significantly greater improvement with fluticasone than placebo in terms of episode-free days among boys, white subjects, participants with an emergency department (ED) visit or hospitalization within the past year, and those who experienced more symptomatic days at baseline. Children with aeroallergen sensitization experienced greater benefits in terms of oral corticosteroid use, urgent care and ED visits, and use of supplemental controller medications. Conclusions: More favorable responses to ICS than placebo in high-risk preschool children over a 2-year period were more likely in those with a ED visit or hospitalization for asthma within the past year, children with aeroallergen sensitization, boys, and white subjects.

KW - Childhood asthma

KW - inhaled corticosteroids

KW - response

UR - http://www.scopus.com/inward/record.url?scp=67349174723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349174723&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2008.12.1120

DO - 10.1016/j.jaci.2008.12.1120

M3 - Article

VL - 123

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 5

ER -